Auriel, E., Hausdorff, J. M., Herman, T., Simon, E. S. and Giladi, N. (2006). Effects of methylphenidate on cognitive function and gait in patients with Parkinson's disease: a pilot study. Clinical Neuropharmacology, 29, 15–17.
Baddeley, A. D., Logie, R., Bressi, S., Della Sala, S. and Spinnler, H. (1986). Dementia and working memory. Quarterly Journal of Experimental Psychology, 38, 603–618.
Berridge, C. W. and Devilbiss, D. M. (2011). Psychostimulants as cognitive enhancers: the prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorder. Biological Psychiatry, 69, e101–111.
Bronnick, K.et al. (2006). Attentional deficits affect activities of daily living in dementia-associated with Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry, 77, 1136–1142.
Cools, R. and D'Esposito, M. (2011). Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biological Psychiatry, 69, e113–125.
Cools, R., Frank, M. J., Gibbs, S. E., Miyakawa, A., Jagust, W. and D'Esposito, M. (2009). Striatal dopamine predicts outcome-specific reversal learning and its sensitivity to dopaminergic drug administration. Journal of Neuroscience, 29, 1538–1543.
Cross, A. J., Crow, T. J., Ferrier, I. N., Johnson, J. A. and Markakis, D. (1984). Striatal dopamine receptors in Alzheimer-type dementia. Neuroscience Letters, 52, 1–6.
Cummings, J. L., Mega, M. S., Gray, K., Rosenberg-Thompson, S., Carusi, D. A. and Gornbein, J. (1994). Neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology, 44, 2308–2314.
David, R.et al. (2008). Striatal dopamine transporter levels correlate with apathy in neurodegenerative diseases: a SPECT study with partial volume effect correction. Clinical Neurology and Neurosurgery, 110, 19–24.
Drye, L. T.et al. (2013). Designing a trial to evaluate potential treatments for apathy in dementia: the Apathy in Dementia Methylphenidate Trial (ADMET). American Journal of Geriatric Psychiatry, 21, 549–559.
Folstein, M. F., Folstein, S. E. and McHugh, P. R. (1975). “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189–198.
Galvin, J. E.et al. (2008). Effects of galantamine on measures of attention: results from 2 clinical trials in Alzheimer disease patients with comparisons to donepezil. Alzheimer Disease and Associated Disorders, 22, 30–38.
Galynker, I., Ieronimo, C., Miner, C., Rosenblum, J., Vilkas, N. and Rosenthan, R. (1997). Methylphenidate treatment of negative symptoms in patients with dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 9, 231–239.
Gorus, E., Lambert, M., De Raedt, R. and Mets, T. (2007). The influence of galantamine on reaction time, attention processes, and performance variability in elderly Alzheimer patients. Journal of Clinical Psychopharmacology, 27, 182–187.
Hendrix, S. B. and Welsh-Bohmer, K. A. (2013). Separation of cognitive domains to improve prediction of progression from mild cognitive impairment to Alzheimer's disease. Alzheimer's Research and Therapy, 5, 22.
Herrmann, N.et al. (2008). Methylphenidate for the treatment of apathy in Alzheimer disease: prediction of response using dextroamphetamine challenge. Journal of Clinical Psychopharmacology, 28, 296–301.
Ivanov, I.et al. (2012). Effects of motivation on reward and attentional networks: an fMRI study. Brain Behavior, 2, 741–753.
Koob, G. F. (1996). Hedonic valence, dopamine and motivation. Molecular Psychiatry, 1, 186–189.
Kuczenski, R., Segal, D. S., Cho, A. K. and Melega, W. (1995). Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methylphenidate. Journal of Neuroscience, 15, 1308–1317.
Lanctôt, K. L.et al. (2007). A SPECT study of apathy in Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 24, 65–72.
Lanctôt, K. L.et al. (2008). Apathy associated with Alzheimer disease: use of dextroamphetamine challenge. American Journal of Geriatric Psychiatry, 16, 551–557.
Marin, R. S., Biedrzycki, R. C. and Firinciogullari, S. (1991). Reliability and validity of the Apathy Evaluation Scale. Psychiatry Research, 38, 143–162.
McGuinness, B., Barrett, S. L., Craig, D., Lawson, J. and Passmore, A. P. (2010). Attention deficits in Alzheimer's disease and vascular dementia. Journal of Neurology, Neurosurgery And Psychiatry, 81, 157–159.
McPherson, S., Fairbanks, L., Tiken, S., Cummings, J. L. and Back-Madruga, C. (2002). Apathy and executive function in Alzheimer's disease. Journal of the International Neuropsychological Society, 8, 373–381.
Mitchell, R. A., Herrmann, N. and Lanctôt, K. L. (2010). The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease. CNS Neuroscience and Therapeutics, 17, 411–427.
Nieoullon, A. and Coquerel, A. (2003). Dopamine: a key regulator to adapt action, emotion, motivation and cognition. Current Opinion in Neurology, 16 (Suppl. 2), S3–9.
Padala, P. R.et al. (2010). Methylphenidate for apathy and functional status in dementia of the Alzheimer type. American Journal of Geriatric Psychiatry, 18, 371–374.
Park, L. Q.et al. (2012). Confirmatory factor analysis of the ADNI Neuropsychological Battery. Brain Imaging and Behavior, 6, 528–539.
Perry, R. J. and Hodges, J. R. (1999). Attention and executive deficits in Alzheimer's disease. A critical review. Brain, 122 (Pt 3), 383–404.
Perry, R. J., Watson, P. and Hodges, J. R. (2000). The nature and staging of attention dysfunction in early (minimal and mild) Alzheimer's disease: relationship to episodic and semantic memory impairment. Neuropsychologia, 38, 252–271.
Rapp, M. A. and Reischies, F. M. (2005). Attention and executive control predict Alzheimer disease in late life: results from the Berlin Aging Study (BASE). American Journal of Geriatric Psychiatry, 13, 134–141.
Rosenberg, P. B.et al. (2013). Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial. Journal of Clinical Psychiatry, 74, 810–816.
Schneider, L. S.et al. (1997). Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders, 11, S22–32.
Storga, D., Vrecko, K., Birkmayer, J. G. and Reibnegger, G. (1996). Monoaminergic neurotransmitters, their precursors and metabolites in brains of Alzheimer patients. Neuroscience Letters, 203, 29–32.
Swanson, J.et al. (1999). Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clinical Pharmacology and Therapeutics, 66, 295–305.
Tucha, O., Mecklinger, L., Laufkotter, R., Klein, H. E., Walitza, S. and Lange, K. W. (2006). Methylphenidate-induced improvements of various measures of attention in adults with attention deficit hyperactivity disorder. Journal of Neural Transmission, 113, 1575–1592.
Vellas, B.et al. (2005). Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease. Current Medical Research and Opinion, 21, 1423–1429.
Wheeler, D. (1981). Wechsler Adult Intelligence Scale–Revised, Manual. New York: Psychological Corporation.